Calla Lily joins $50M program targeting antibiotic resistance A new intravaginal drug delivery platform has been selected to investigate whether localized UTI treatment can reduce the collateral effects of systemic antibiotics. Written byBree Foster, PhD

https://www.drugdiscoverynews.com/calla-lily-joins-50m-program-targeting-antibiotic-resistance-17427 Antimicrobial resistance (AMR) is increasingly recognized as a consequence not only of antibiotic-resistant bacteria, but also of the collateral effects of antibiotic treatment. Antibiotic administration can profoundly alter the composition and diversity of the gut microbiota, disrupt homeostasis, and create selective pressure that promotes the proliferation of antibiotic-resistant bacteria. According to Wellcome Leap, 85–90 percent of bacterial infections are localized, while nearly all antibiotics are delivered systemically.